scispace - formally typeset
J

Jerome Eberhardt

Researcher at Scripps Research Institute

Publications -  15
Citations -  1192

Jerome Eberhardt is an academic researcher from Scripps Research Institute. The author has contributed to research in topics: AutoDock & Druggability. The author has an hindex of 8, co-authored 14 publications receiving 265 citations. Previous affiliations of Jerome Eberhardt include Scripps Health & French Institute of Health and Medical Research.

Papers
More filters
Journal ArticleDOI

AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings.

TL;DR: This work implemented Python bindings to facilitate scripting and the development of docking workflows in AutoDock Vina 1.2.0, an effort toward the unification of the features of the autoDock4 and AutoD Dock Vina docking engines.
Journal ArticleDOI

Allostery in Its Many Disguises: From Theory to Applications

Shoshana J. Wodak, +41 more
- 02 Apr 2019 - 
TL;DR: An overview of the progress and remaining limitations in the understanding of the mechanistic foundations of allostery gained from computational and experimental analyses of real protein systems and model systems is provided.
Journal ArticleDOI

Structural Insights into the Molecular Mechanism of Vitamin D Receptor Activation by Lithocholic Acid Involving a New Mode of Ligand Recognition

TL;DR: Biological activity assays, structural analysis, and molecular dynamics simulations indicate that the recognition of two ligand molecules is crucial for VDR agonism by LCA, and the unique binding mode of LCA provides clues for the development of new chemical compounds that target alternative binding sites for therapeutic applications.
Journal ArticleDOI

Comparison of affinity ranking using AutoDock-GPU and MM-GBSA scores for BACE-1 inhibitors in the D3R Grand Challenge 4

TL;DR: The MM-GBSA protocol is sensitive to details in the protein-ligand system and neutral ligands are more adapted to MM- GBSA calculations than charged ligands, and predicted binding affinities depend on the initial conformation of the BACE-1 receptor.
Journal ArticleDOI

Structural Basis of Altered Potency and Efficacy Displayed by a Major in Vivo Metabolite of the Antidiabetic PPARγ Drug Pioglitazone

TL;DR: Results indicating that Pio hydroxylation affects its potency and efficacy as a PParγ agonist contributes to the understanding of PPARγ-drug metabolite interactions.